4.7 Article

Plasma neuropeptide Y and cognitive impairment after acute ischemic stroke

期刊

JOURNAL OF AFFECTIVE DISORDERS
卷 317, 期 -, 页码 221-227

出版社

ELSEVIER
DOI: 10.1016/j.jad.2022.08.052

关键词

Neuropeptide Y; Post-stroke cognitive impairment; Ischemic stroke; Montreal cognitive assessment score

资金

  1. Natural Science Foundation of Jiangsu Province [BK20190818]
  2. National Natural Science Foundation of China [81903387, 81773522]
  3. Suzhou Science and Technology Project [SYS2019023]
  4. Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions, China

向作者/读者索取更多资源

Elevated plasma NPY levels are associated with a decreased risk of cognitive impairment in patients with acute ischemic stroke. Plasma NPY may serve as a predictive factor and potential therapeutic target for post-stroke cognitive impairment (PSCI).
Background and purpose: Neuropeptide Y (NPY) has a modulatory role in learning and memory, and is involved in the pathophysiology of neurodegenerative diseases. However, there was no population-based evidence on the relationship between NPY and post-stroke cognitive impairment (PSCI). We aimed to prospectively examine the association between plasma NPY and cognitive impairment among patients with acute ischemic stroke. Methods: On the basis of samples from the China Antihypertensive Trial in Acute Ischemic Stroke, 593 patients with baseline plasma NPY levels were finally included in this study. The study outcome was cognitive impairment (Montreal Cognitive Assessment score < 26) at 3 months after ischemic stroke. Logistic regression models were used to estimate the risk of cognitive impairment. Results: After 3 months of follow-up, 422 participants (71.2 %) experienced cognitive impairment. Multivariable-adjusted odds ratio (95 % confidence interval) for the highest tertile of NPY was 0.58 (0.36-0.92) compared with the lowest tertile. Each 1-SD higher log-NPY was associated with a decreased risk of 20 % (95 % confidence interval 2 %-34 %) for PSCI. The addition of plasma NPY to the basic model with conventional risk factors improved the risk reclassification (continuous net reclassification index was 22.8 %, p = 0.01; integrated discrimination improvement was 0.9 %, p = 0.02) for PSCI. Limitations: We measured plasma NPY only once at baseline and failed to explore the association between NPY changes and PSCI. Conclusions: Elevated plasma NPY levels were associated with a decreased risk of cognitive impairment, suggesting plasma NPY may serve as a predictive factor and potential therapeutic target for PSCI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据